Chief Executive Officer, Anixa Biosciences
Search every verified Amit Kumar interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Amit Kumar, Chairman and CEO of Anixa Biosciences, appeared in two RedChip programs in September 2026 to discuss the company's breast cancer vaccine program. In an interview on September 3, he commented on recent Phase 3 data from Merck and Moderna's personalized mRNA melanoma vaccine, calling it "fantastic news" and "a great scientific achievement," while stating that the field is "starting to enter the age of cancer vaccines." He described Anixa's vaccine, developed with Cleveland Clinic and funded by the U.S. Department of Defense, as an off-the-shelf peptide-based approach designed to treat and prevent breast cancer, in contrast to personalized mRNA vaccines. In a September 12 appearance, Kumar discussed the potential impact of the vaccine, saying that while society has become effective at keeping breast cancer patients alive, the treatment process is "brutal" and expensive. He described a future scenario where women could receive three shots to prevent breast cancer, potentially eliminating the disease as has been done for infectious diseases like smallpox and polio. The segment also noted that Anixa's Phase 1 trial met all primary endpoints, with positive results in 74% of patients, and highlighted insider buying from Kumar and board members.
This week's episode of Small Stocks Big Money features exclusive interviews with senior executives from Anixa Biosciences, Inc. (NASDAQ: ANIX) & Nexalin Technology, Inc. (NASDAQ: NXL) Explore the latest insights and updates in the world of small-cap stocks. Visit RedChip.com to learn more.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (Nasdaq: ANIX), joins RedChip to discuss the Company's breast cancer vaccine program and the broader shift toward effective cancer vaccines, alongside patient perspective from Phase 1 trial participant Sherry. Anixa is a clinical-stage biotechnology company developing a therapeutic and preventive breast cancer vaccine in collaboration with Cleveland Clinic and with funding support from the U.S. Department of Defense. Unlike personalized mRNA cancer vaccines, Anixa's vaccine is an off-the-shelf peptide-based approach designed to be availabl…
In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Amit Kumar, PhD, CEO of Anixa Biosciences (NASDAQ: ANIX) to discuss t-cells and Anixa's two clinical developments, one involving the modification of CAR-T technology to overcome the challenges of treating solid tumors, specifically ovarian cancer, and the other, an innovative breast cancer vaccine that trains antigen-specific t-cells to recognize and attack breast cancer cells, especially those from triple-negative breast cancer, the most aggressive form of breast cancer. Kumar also talks abou…
Send us Fan Mail (https://www.buzzsprout.com/2176476/fa...) In this episode of the Small-Cap Spotlight, we welcome back Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences (NASDAQ: ANIX) who explains why 2026 is shaping up to be a pivotal year for the company. Building on the momentum of 2025, Dr. Kumar walks us through key developments across Anixa’ clinical pipeline and strategic direction. He outlines the company’s plans as its breast cancer vaccine progresses into Phase 2 following strong Phase 1 results. At the same time, he emphasizes the striking efficacy signals emerging from the…
Anixa Biosciences (Nasdaq: ANIX) is advancing a clinical-stage oncology pipeline focused on cancer vaccines and CAR-T therapy, led by its breast cancer vaccine program developed with Cleveland Clinic and supported by U.S. Department of Defense funding. In our exclusive interview, Dr. Amit Kumar, Chairman & CEO of Anixa Biosciences, discusses the company’s breast cancer vaccine targeting alpha-lactalbumin, its completed Phase 1 study, the path toward Phase 2, and the long-term vision of potentially preventing breast cancer before it starts. Dr. Kumar also highlights Anixa’s ovarian cancer CAR-…
On Monday we introduced you to Chase Johnson, who was part of the first phase of a clinical trial to develop a preventive breast cancer vaccine. The trials are a joint effort between The Cleveland Clinic and Anixa Biosciences, a bio-tech company that develops therapies and vaccines. WGCU’s Jennifer Crawford had the chance to speak with Doctor Amit Kumar, Anixa Biosciences’ CEO and chairman, to learn more about the results of the trials and if their results show anything promising in the battle against breast cancer.
Cancer immunotherapy is evolving beyond conventional treatment models, creating new public-market opportunities in prevention, targeted cell therapy, and next-generation oncology platforms. In this replay of Anixa Biosciences’ (Nasdaq: ANIX) presentation and Q&A from RedChip’s Biotech Resurgence conference, Chairman and CEO Amit Kumar explains how the company is advancing both a breast cancer vaccine program and a novel ovarian cancer CAR-T platform. Watch this presentation and Q&A to learn about: • The completed Phase 1 breast cancer vaccine study and the company’s reported immune-response a…
This CEO Is Creating A Vaccine To Cure Breast Cancer - Meet Dr. Amit Kumar, Chairman/CEO of Anixa Biosciences $ANIX Guest Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences Anixa Biosciences, www.Anixa.com, NASDAQ:ANIX Company Info Anixa Biosciences NASDAQ:ANIX https://www.Anixa.com/ Amit's Bio: AMIT KUMAR, PH.D. Chairman & Chief Executive Officer Dr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has work…
Dr. Amit Kumar, CEO of Anixa Biosciences, speaks to Nisha P S about the company’s promising breast cancer vaccine developed with the Cleveland Clinic. Phase 1 trials showed 70–75% strong immune response. The goal is to stop breast cancer before it starts. Phase 2 is set to begin next year. #breastcancer #vaccine #anixa #amitkumar #cancerprevention #research #clevelandclinic #womenshealth #medicalinnovation #ai #medicine #clinicaltrials #dod --- ▶For the latest news and analysis - https://thefederal.com/ ▶RSS Feed - https://thefederal.com/google_feeds.xml ▶For more explainers, and interesti…
The 4th ANNUAL NeauxCancer Conference by CAGLA (The Cancer Advocacy Group of Louisiana) was held from March 27th – March 29th, 2025 at the The Roosevelt New Orleans. The NeauxCancer Conference by CAGLA unites individuals dedicated to combating cancer. This multi-day day, multi-track CME/CE conference attracts a large number of medical oncologists, cancer surgeons, radiation oncologists, and other physicians as well as advanced practice providers, medical trainees, nurses, pharmacists, and other healthcare professionals. The conference offers a wide variety of multi-disciplinary didactic sess…
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Amit Kumar, a seasoned leader in the biotech industry and the current CEO & Chairman of Anixa Biosciences. Amit's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO of CombiMatrix, a key player in molecular diagnostics, as well as GFF, and is also the Executive Chairman and co-founder of Actym Therapeutics, a company advancing immune oncology treatments. Now, at the helm of Anixa Biosciences, Amit is focused on addressing so…
Sully & Crew talk about various topics, and they talk with Prof. Jonathan Javitt, MD, MPH of NRX Pharmaceuticals about their therapy for depression & suicidal ideation, and Les Goldman of Northwest Biotherapeutics about their vaccine for GBM cancer. Also, Amit Kumar of Anixa Biosciences about their immunotherapies for cancer & a breast cancer vaccine. Air Date 7/11/24 #bigbizshow #biztv #sully #mikecosta #maryburtgodwin #gregtodorov #howiefont #profjonathanjavitt #mdmph #nrxpharmaceuticals #depression #suicidalideation #lesgoldman #northwestbiotherapeutics #cancervaccine #gbmcancer #braincan…
Sign in to search the full transcript archive, filter by topic, and access every quote from Amit Kumar.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans